Brand name | Active ingredient | Mechanism of action | Year approved |
---|---|---|---|
Adipex-P, Ionamin | Phentermine | Precise mechanism unknown: norepinephrine-dopamine releasing agent | 1959 |
Alli, Xenicala | Orlistat | Inhibits gastric and pancreatic lipases | 1999 |
Belviqa | Lorcaserin | Selective 5-HT2C receptor agonist | 2012 |
Contrave, Mysimbaa | Naltrexone + bupropion | Bupropion: re-uptake inhibitor and releasing agent of norepinephrine and a nicotinic acetylcholine receptor antagonist; naltrexone augments bupropion’s activation of proopiomelanocortin (POMC) | 2014 |
Didrex | Benzphetamine | Precise mechanism unknown: norepinephrine-dopamine releasing agent | 1960 |
Obezine | Phendimetrazine | Precise mechanism unknown: norepinephrine-dopamine releasing agent | 1961 |
Qsymia, Qnexaa | Phentermine + topiramate | The precise mechanism of action for both drugs is unknown: phentermine is a norepinephrine-dopamine releasing agent; topiramate augments gamma-aminobutyrate (GABA), inhibits α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate receptors, and inhibits carbonic anhydrase | 2012 |
Saxenda, Victozaa | Liraglutide | Glucagon-like peptide-1 receptor agonist | 2014 |
Tenuate Dospan | Diethylpropion | Precise mechanism unknown: norepinephrine-dopamine releasing agent | 1959 |